ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Translational Session

Making Sense Out of Nrf2

October 23, 2020 | 10:00 AM - 12:00 PM

Location: On-Demand

Session Description

The Keap1/Nrf2 pathway has received great attention in kidney disease research. Preclinical research and initial clinical trials generally showed positive results. However, there is concern over harms such as fluid accumulation, proteinuria, and hypomagnesemia. These various effects require closer study, particularly in light of ongoing clinical trials in renal and nonrenal disease, including new uses for Alport syndrome and PKD. This session evaluates the basic science, translational, and clinical trials associated with Nrf2 activation.

Learning Objective(s)

  • Describe the basic principles of Nrf2 effects on different kidney cell types, including podocytes, mesangial cells, and tubular epithelial cells
  • Report updated knowledge on the protective effects of Nrf2 on the kidney
  • Explain the potential adverse effects of Nrf2 activators
  • Discuss the role of Nrf2 enhancers in DKD, Alport syndrome, and PKD

Learning Pathway(s)

  • Chronic Kidney Disease
  • Glomerular Diseases

Moderators

  • Rachel Lennon, MBBS, PhD
  • Roderick J. Tan, MD, PhD

Presentations

  • Discovering the Nrf2-Keap1 Pathway: An Overview
    10:00 AM - 10:30 AM
    Norio Suzuki, PhD
  • Positive and Negative Findings from Clinical Trials of Bardoxolone
    10:30 AM - 11:00 AM
    Masaomi Nangaku, MD, PhD 
  • Potential Adverse Effects of Nrf2 Activation
    11:00 AM - 11:30 AM
    Ariela Benigni, PhD 
  • The Role of Nrf2 in Aging Processes
    11:30 AM - 12:00 PM
    Peter Stenvinkel, MD, PhD, FASN